XTLB

NASDAQ 已收盘

XTL Biopharmaceuticals

1.37 USD
▼-0.11-7.43%
盘后 1.33 -2.92%
2026-11-20
市值
$4.77M
市盈率
—
EPS
-1.09
股息率
—
52 周区间
1.37 – 5.64
成交量
1.78K
Beta
0.47
目标价
—
52W 低 1.3752W 高 5.64
价格走势

公司简介

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company’s lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies...